203 related articles for article (PubMed ID: 29907471)
1. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor.
Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H
Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471
[TBL] [Abstract][Full Text] [Related]
2. Discovery and biological evaluation of novel pyrazolopyridine derivatives as potent and orally available PI3Kδ inhibitors.
Hamajima T; Takahashi F; Kato K; Mukoyoshi K; Yoshihara K; Yamaki S; Sugano Y; Moritomo A; Yamagami K; Yokoo K; Fukahori H
Bioorg Med Chem; 2018 May; 26(9):2410-2419. PubMed ID: 29631787
[TBL] [Abstract][Full Text] [Related]
3. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
4. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor.
Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H
Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Degorce SL; Boyd S; Curwen JO; Ducray R; Halsall CT; Jones CD; Lach F; Lenz EM; Pass M; Pass S; Trigwell C
J Med Chem; 2016 May; 59(10):4859-66. PubMed ID: 27078757
[TBL] [Abstract][Full Text] [Related]
7. Identification of highly potent and selective PI3Kδ inhibitors.
Marcoux D; Qin LY; Ruan Z; Shi Q; Ruan Q; Weigelt C; Qiu H; Schieven G; Hynes J; Bhide R; Poss M; Tino J
Bioorg Med Chem Lett; 2017 Jul; 27(13):2849-2853. PubMed ID: 28209465
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
[TBL] [Abstract][Full Text] [Related]
9. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and SAR study of potent and selective PI3Kδ inhibitors.
Bui M; Hao X; Shin Y; Cardozo M; He X; Henne K; Suchomel J; McCarter J; McGee LR; San Miguel T; Medina JC; Mohn D; Tran T; Wannberg S; Wong J; Wong S; Zalameda L; Metz D; Cushing TD
Bioorg Med Chem Lett; 2015 Mar; 25(5):1104-9. PubMed ID: 25666823
[TBL] [Abstract][Full Text] [Related]
11. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
12. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
13. Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.
Cushing TD; Hao X; Shin Y; Andrews K; Brown M; Cardozo M; Chen Y; Duquette J; Fisher B; Gonzalez-Lopez de Turiso F; He X; Henne KR; Hu YL; Hungate R; Johnson MG; Kelly RC; Lucas B; McCarter JD; McGee LR; Medina JC; San Miguel T; Mohn D; Pattaropong V; Pettus LH; Reichelt A; Rzasa RM; Seganish J; Tasker AS; Wahl RC; Wannberg S; Whittington DA; Whoriskey J; Yu G; Zalameda L; Zhang D; Metz DP
J Med Chem; 2015 Jan; 58(1):480-511. PubMed ID: 25469863
[TBL] [Abstract][Full Text] [Related]
14. Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430).
Gonzalez-Lopez de Turiso F; Hao X; Shin Y; Bui M; Campuzano ID; Cardozo M; Dunn MC; Duquette J; Fisher B; Foti RS; Henne K; He X; Hu YL; Kelly RC; Johnson MG; Lucas BS; McCarter J; McGee LR; Medina JC; Metz D; San Miguel T; Mohn D; Tran T; Vissinga C; Wannberg S; Whittington DA; Whoriskey J; Yu G; Zalameda L; Zhang X; Cushing TD
J Med Chem; 2016 Aug; 59(15):7252-67. PubMed ID: 27411843
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
[TBL] [Abstract][Full Text] [Related]
16. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
Sutherlin DP; Baker S; Bisconte A; Blaney PM; Brown A; Chan BK; Chantry D; Castanedo G; DePledge P; Goldsmith P; Goldstein DM; Hancox T; Kaur J; Knowles D; Kondru R; Lesnick J; Lucas MC; Lewis C; Murray J; Nadin AJ; Nonomiya J; Pang J; Pegg N; Price S; Reif K; Safina BS; Salphati L; Staben S; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Ultsch M; Waszkowycz B; Wei B
Bioorg Med Chem Lett; 2012 Jul; 22(13):4296-302. PubMed ID: 22672799
[TBL] [Abstract][Full Text] [Related]
17. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).
Deng X; S Gray N
Expert Opin Ther Pat; 2012 Jun; 22(6):709-13. PubMed ID: 22607035
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.
Bahekar R; Dave B; Soman S; Patel D; Chopade R; Funde R; Kumar J; Sachchidanand S; Giri P; Chatterjee A; Mahapatra J; Vyas P; Ghoshdastidar K; Bandyopadhyay D; Desai RC
Bioorg Med Chem Lett; 2019 Jun; 29(11):1313-1319. PubMed ID: 30975623
[TBL] [Abstract][Full Text] [Related]
19. Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases.
Liu K; Li D; Zheng W; Shi M; Chen Y; Tang M; Yang T; Zhao M; Deng D; Zhang C; Liu J; Yuan X; Yang Z; Chen L
J Med Chem; 2021 Jul; 64(13):8951-8970. PubMed ID: 34138567
[TBL] [Abstract][Full Text] [Related]
20. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
